Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie mające na celu udokumentowanie i dalsze opisanie długoterminowego bezpieczeństwa i skuteczności palowarotenu u osób chorych na fibrodysplazję kostniejącą postępującą (FOP) (FOPal)

20 października 2026 zaktualizowane przez: Ipsen

Międzynarodowe badanie obserwacyjne w celu dalszego opisu długoterminowego bezpieczeństwa i skuteczności palowarotenu u pacjentów z fibrodysplazją kostniejącą postępującą (FOP)

The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP).

FOP is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally present (heterotopic ossification (HO)).

HO is often preceded by painful, recurrent episodes of soft tissue swelling (flare-ups).

This registry study will take place in countries where the treatment, known as palovarotene, has been approved for use. Participants will either be treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information) or untreated with palovarotene.

The main aim of this registry study will be to collect and assess real-world safety data on children and adult participants with FOP treated with palovarotene.

This registry study will also describe the effectiveness of palovarotene in exposed participants, including the effect on everyday activities and physical performance.

In addition, this registry study aims to descriptively compare key safety outcomes (i.e. flare-up episodes, growth outcomes, and bone fractures) between participants exposed and unexposed to palovarotene.

Przegląd badań

Status

Rekrutacyjny

Warunki

Typ studiów

Obserwacyjny

Zapisy (Szacowany)

100

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

      • Edmonton, Kanada
        • Rekrutacyjny
        • Edmonton Clinic Health Academy (ECHA)- University of Alberta
      • Oakville, Kanada
        • Aktywny, nie rekrutujący
        • Bone Research and Education Centre
      • Toronto, Kanada
        • Rekrutacyjny
        • University Health Network (UHN) - Toronto General
    • California
      • San Francisco, California, Stany Zjednoczone, 94103
        • Rekrutacyjny
        • The Regents of the University of California
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
        • Rekrutacyjny
        • The Trustees of the University of Pennsylvania, Office of Clinical Research-Legal Services, Perelman School of Medicine

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

8 lat i starsze (Dziecko, Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

Adults and children with FOP who have been prescribed palovarotene, as per local label, by their treating physician for which informed consent has been obtained and maintained. Participants cannot be included if they are currently participating in a palovarotene clinical trial or an interventional clinical trial for FOP or if they have any contraindication for palovarotene (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).

Opis

Inclusion Criteria :

  • Adult or child with FOP who have been prescribed palovarotene (prior to and independently of the decision to enroll the patient in this registry study and as per local label) by their treating physician according to the locally approved product information;
  • Signed informed consent as per local regulations must be obtained and maintained. Consent/assent from the participant should be obtained as appropriate before any registry study data collection are conducted. If applicable, parents or legally authorized representatives must give signed informed consent.

Exclusion Criteria :

  • Currently participating in a palovarotene clinical trial;
  • Currently participating in any interventional clinical trial for FOP;
  • Have any contraindication to palovarotene as per the locally approved label (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Modele obserwacyjne: OTHER
  • Perspektywy czasowe: PROSPECTIVE

Kohorty i interwencje

Grupa / Kohorta
Exposed Cohort

Participants treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information)

Unexposed Cohort

Participants untreated with palovarotene

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), whether or not they are considered as related to palovarotene
Ramy czasowe: From Baseline up to 30 days after the last palovarotene dose.

Adverse events will be coded according to MedDRA and will be classified by Preferred Term (PT) and system organ class (SOC).

From Baseline up to 30 days after the last palovarotene dose.
Percentage of Participants With Serious and Non-serious treatment-related TEAEs
Ramy czasowe: From Baseline up to 30 days after the last palovarotene dose.

Adverse events will be coded according to MedDRA and will be classified by PT and SOC.

From Baseline up to 30 days after the last palovarotene dose.
Percentage of Participants With all serious TEAEs, whether or not they are considered as related to the palovarotene
Ramy czasowe: From Baseline up to 30 days after the last palovarotene dose.

Adverse events will be coded according to MedDRA and will be classified by PT and SOC.

From Baseline up to 30 days after the last palovarotene dose.
Percentage of Participants With nonserious TEAEs whether or not they are considered as related to the palovarotene.
Ramy czasowe: From Baseline up to 30 days after the last palovarotene dose.

Adverse events will be coded according to MedDRA and will be classified by PT and SOC.

From Baseline up to 30 days after the last palovarotene dose.

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Liczba zaostrzeń
Ramy czasowe: Od 12 miesięcy przed włączeniem Wartość bazowa do jedenastu lat.
Od 12 miesięcy przed włączeniem Wartość bazowa do jedenastu lat.
Liczba lokalizacji, których to dotyczy, na uczestnika
Ramy czasowe: Od linii bazowej i co roku do jedenastu lat.
Od linii bazowej i co roku do jedenastu lat.
Ewolucja dotkniętej lokalizacji (ile razy wpływ jest na lokalizację) na lokalizację
Ramy czasowe: Od linii bazowej i co roku do jedenastu lat.
Od linii bazowej i co roku do jedenastu lat.
Średnia dawka/rok palowarotenu dla uczestników z FOP odsłoniętą i nienaświetloną na palowaroten do przewlekłego leczenia
Ramy czasowe: Od linii bazowej i co sześć miesięcy do jedenastu lat.
Od linii bazowej i co sześć miesięcy do jedenastu lat.
Średnia dawka/cykl palowarotenu dla uczestników z FOP odsłoniętą i nienaświetloną na palowaroten w celu zabiegu mnóstwa
Ramy czasowe: Od linii bazowej i co sześć miesięcy do jedenastu lat.
Od linii bazowej i co sześć miesięcy do jedenastu lat.
Change from Baseline in Cumulative Analogue Joint Involvement Scale (CAJIS) total score
Ramy czasowe: From Baseline and every six months up to eleven years.

The CAJIS is an objective measure of joint movement completed by the Investigator to document total joint involvement. The CAJIS total score is calculated as the sum of the scores of all joints/regions and ranges from 0 (no involvement) to 30 (maximally involved).

From Baseline and every six months up to eleven years.
Change from Baseline in use of assistive devices
Ramy czasowe: From Baseline and every six months up to eleven years.

Assistive devices is a questionnaire to assess the assistive devices used by particpants and adaptations for their daily living.

From Baseline and every six months up to eleven years.
Change from Baseline in percent of worst score for Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire (FOP-PFQ) total score
Ramy czasowe: From Baseline and every six months up to eleven years.

Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire (FOP-PFQ) consists of questions which are scored on a scale of 1 to 5, lower scores indicating that the participant has more difficulties.

From Baseline and every six months up to eleven years.
Change from Baseline in observed and percent predicted Forced Vital Capacity (FVC)
Ramy czasowe: From Baseline and every six months up to eleven years.

The lung function parameters of observed FVC (liters) and percent predicted FVC are obtained by spirometry.

From Baseline and every six months up to eleven years.
Change from Baseline in observed and percent predicted Forced Expiratory Volume in one second (FEV1)
Ramy czasowe: From Baseline and every six months up to eleven years.

The lung function parameters of observed FEV1 (liters) and percent predicted FEV1 are obtained by spirometry.

From Baseline and every six months up to eleven years.
Change from Baseline in absolute and percent predicted FEV1/FVC ratio
Ramy czasowe: From Baseline and every six months up to eleven years.

The lung function parameters of the absolute and percent predicted FEV1/FVC ratio are obtained by spirometry.

From Baseline and every six months up to eleven years.
Change from Baseline in observed and percent predicted Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)
Ramy czasowe: From Baseline and every six months up to eleven years.

The lung function parameters of observed (traditional unit of mL/min/mmHg or SI unit of mmol/min/kPa) and percent predicted DLCO is obtained by the DLCO test.

From Baseline and every six months up to eleven years.
Change from Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) physical and mental function (mean global physical and mental health score converted into T-scores) for participants ≥15 years old
Ramy czasowe: From Baseline and every six months up to eleven years.

PROMIS Global Health Scale for the adult version, the global physical health and global mental health scores will be calculated as follows:

  • Global physical health scores will be calculated as the sum of scores from Questions 3, 6, 7 and 8 and will range from 4 (worse health) to 20 (better health);
  • Global mental health scores will be calculated as the sum of scores from Questions 2, 4, 5 and 10 and will range from 4 (worse health) to 20 (better health).
From Baseline and every six months up to eleven years.
Change from Baseline in PROMIS overall quality of life (QoL) (mean total score converted into T-scores) for participants <15 years old
Ramy czasowe: From Baseline and every six months up to eleven years.

PROMIS Global Health Scale for the paediatric version, the total score will be calculated as the sum of scores from the first 7 questions and will range from 7 (worse health) to 35 (better health).

If more than 3 questions contributing to the total score are missing, the total score will not be calculated. It will be considered as missing.

From Baseline and every six months up to eleven years.
Change from Baseline in annualized number of Investigator-reported flare-ups by body location and overall
Ramy czasowe: From Baseline and every six months up to eleven years.

The annualized number of flare-ups will be derived from the number of flare-ups the participant experienced since last visit.

From Baseline and every six months up to eleven years.
Number of flare-up outcomes
Ramy czasowe: From Baseline and every six months up to eleven years.

Number of flare-up outcomes as measured by new bone growth, restricted movement at each visit will be reported.

From Baseline and every six months up to eleven years.
Flare-up Duration
Ramy czasowe: From Baseline and every six months up to eleven years.

Flare-up duration will be assessed by body location and overall, at each visit.

From Baseline and every six months up to eleven years.
Movement mobility change
Ramy czasowe: From Baseline and annually up to eleven years.

Assessed by key body location: better movement/the same movement/slightly worse movement/moderately worse movement/severely worse movement)

From Baseline and annually up to eleven years.
Movement mobility outcomes: Percentage of participants with new bone growth overall and by flare-up status
Ramy czasowe: From Baseline and every six months up to eleven years.

The number of extra bone growths, location of the extra bone growth, whether it was preceded by injury, illness, vaccination and/or other events, whether it was preceded by pain, soft tissue swelling, decreased range of motion, stiffness, redness, or warmth, extra bone growth start and stop date and whether it is ongoing, will be collected.

From Baseline and every six months up to eleven years.
Percentage of participants with any fractures overall
Ramy czasowe: From baseline up to 30 days after the last palovarotene dose.

Assessed by radiological imaging and clinical examination.

From baseline up to 30 days after the last palovarotene dose.
Change from Baseline in annualized number of fractures by body location and overall
Ramy czasowe: From baseline up to 30 days after the last palovarotene dose.

Assessed by radiological imaging and clinical examination.

From baseline up to 30 days after the last palovarotene dose.
Incidence of pregnancy
Ramy czasowe: From Baseline and every month up to 30 days after the last palovarotene dose.

A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy and the health status of the baby will be verified

From Baseline and every month up to 30 days after the last palovarotene dose.
Description of pregnancy characteristics and outcomes
Ramy czasowe: From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.

A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy.

From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
Description of pregnancy related Adverse Events (AEs)
Ramy czasowe: From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.

A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy.

From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
Description of birth and developmental outcomes through the first year after birth
Ramy czasowe: From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.

A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy.

From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
Description of birth and developmental outcomes through the first year after birth
Ramy czasowe: From Baseline and every six months up to eleven years.

Linear height and knee height velocity will be derived for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached.

From Baseline and every six months up to eleven years.
Change from Baseline in height z-score
Ramy czasowe: From Baseline and every six months up to eleven years.

Linear height z-score will be derived for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached.

From Baseline and every six months up to eleven years.
Mean difference between chronological age and bone age
Ramy czasowe: From Baseline and every six months up to eleven years.

Bone age (assessment as per the SmPC/PI) and chronological age will be collected for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached.

From Baseline and every six months up to eleven years.
Frequency of premature physeal closure (PPC) overall
Ramy czasowe: From baseline up to 30 days after the last palovarotene dose

Epiphyseal status ("open" or "closed") (assessment as per the SmPC/PI) will be collected for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached.

From baseline up to 30 days after the last palovarotene dose

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Dyrektor Studium: Ipsen Medical, Director, Ipsen

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

5 grudnia 2024

Zakończenie podstawowe (Szacowany)

5 grudnia 2035

Ukończenie studiów (Szacowany)

5 grudnia 2035

Daty rejestracji na studia

Pierwszy przesłany

6 października 2023

Pierwszy przesłany, który spełnia kryteria kontroli jakości

13 października 2023

Pierwszy wysłany (Rzeczywisty)

18 października 2023

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

23 października 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

20 października 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • CLIN-60120-453

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Ramy czasowe udostępniania IPD

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Kryteria dostępu do udostępniania IPD

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .